SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): MAY 29, 2002
------------
INTERLEUKIN GENETICS, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 000-23413 94-3123681
--------------- ------------- ------------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification No.)
incorporation)
135 BEAVER STREET, WALTHAM, MA 02452
---------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (781) 398-0700
--------------
ITEM 5. OTHER EVENTS.
------ ------------
On May 29 2002, Interleukin Genetics, Inc. publicly disseminated a press release
announcing a clinical study with researchers at UnitedHealth Group's Center for
Health Care Policy & Evaluation to determine the influence of genetic markers on
an individual's response to anti-IL-1 and anti-TNFa therapy in adults with
rheumatoid arthritis.
The information contained in the press release is incorporated herein by
reference and filed as Exhibit 99.1 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
------ ---------------------------------
(c) Exhibit.
99.1 Press Release dated May 29, 2002.
2
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
INTERLEUKIN GENETICS, INC.
--------------------------
(Registrant)
Date: May 30, 2002 /s/ Fenel M. Eloi
----------------------------------------------
Fenel M. Eloi, Vice President, Chief Operating
Officer and Chief Financial Officer
3
EXHIBIT INDEX
-------------
Exhibit
Number Description
-------- -----------
99.1 Press Release dated May 29, 2002
4